Guest Column | August 11, 2020

CBER Takes On More Oversight Of Biologic & Biosimilar Master Files

By Michael Cooper, Clinical and Regulatory Affairs, Pharmatech Associates

Folders-iStock-1165040211

This article is currently retracted and is being revised to correct certain inaccuracies. Look for a revised version of the article here soon.